APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuraminidase Inhibitor

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neuraminidase Inhibitor Industry Growth and Trends Forecast to 2032

31 December 202590 pages

Choose your research edition.

Industry ResearchNeuraminidase Inhibitor Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuraminidase Inhibitor Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Neuraminidase Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuraminidase Inhibitor Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuraminidase Inhibitor Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Neuraminidase Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, Daiichi Sankyo and BioCryst, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neuraminidase Inhibitor market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neuraminidase Inhibitor market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neuraminidase Inhibitor market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neuraminidase Inhibitor.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neuraminidase Inhibitor market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neuraminidase Inhibitor Market by Company

GlaxoSmithKline

Gilead Sciences

F. Hoffman-La Roche

Daiichi Sankyo

BioCryst

Neuraminidase Inhibitor Segment by Type

Oseltamivir

Laninamivir

Peramivir

Zanamivir

Neuraminidase Inhibitor Segment by Application

Hospital Pharmacies

Drug Stores

Retail Stores

Others

Neuraminidase Inhibitor Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neuraminidase Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oseltamivir Table 2. Major Company of Laninamivir Table 3. Major Company of Peramivir Table 4. Major Company of Zanamivir Table 5. Global Neuraminidase Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 7. Global Neuraminidase Inhibitor Sales Market Share in Volume by Type (2021-2026) Table 8. Global Neuraminidase Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 9. Global Neuraminidase Inhibitor Sales Market Share in Value by Type (2021-2026) Table 10. Global Neuraminidase Inhibitor Price by Type (2021-2026) & (US$/Unit) Table 11. Global Neuraminidase Inhibitor Sales by Type (2027-2032) & (K Units) Table 12. Global Neuraminidase Inhibitor Sales Market Share in Volume by Type (2027-2032) Table 13. Global Neuraminidase Inhibitor Sales by Type (2027-2032) & (US$ Million) Table 14. Global Neuraminidase Inhibitor Sales Market Share in Value by Type (2027-2032) Table 15. Global Neuraminidase Inhibitor Price by Type (2027-2032) & (US$/Unit) Table 16. North America Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 17. North America Neuraminidase Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 19. Europe Neuraminidase Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 21. Asia-Pacific Neuraminidase Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 23. Latin America Neuraminidase Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Neuraminidase Inhibitor Sales by Type (2021-2026) & (K Units) Table 25. Middle East and Africa Neuraminidase Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 26. Neuraminidase Inhibitor Industry Trends Table 27. Neuraminidase Inhibitor Industry Drivers Table 28. Neuraminidase Inhibitor Industry Opportunities and Challenges Table 29. Neuraminidase Inhibitor Industry Restraints Table 30. Global Neuraminidase Inhibitor Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Neuraminidase Inhibitor Revenue Market Share by Company (2021-2026) Table 32. Global Neuraminidase Inhibitor Sales by Company (2021-2026) & (K Units) Table 33. Global Neuraminidase Inhibitor Sales Share by Company (2021-2026) Table 34. Global Neuraminidase Inhibitor Market Price by Company (2021-2026) & (US$/Unit) Table 35. Global Neuraminidase Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Neuraminidase Inhibitor Major Company Production Sites and Headquarters Table 37. Global Neuraminidase Inhibitor Company, Product Type & Application Table 38. Global Neuraminidase Inhibitor Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Neuraminidase Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Neuraminidase Inhibitor Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Neuraminidase Inhibitor Sales by Region (2021-2026) & (K Units) Table 43. Global Neuraminidase Inhibitor Sales Market Share in Volume by Region (2021-2026) Table 44. Global Neuraminidase Inhibitor Sales by Region (2021-2026) & (US$ Million) Table 45. Global Neuraminidase Inhibitor Sales Market Share in Value by Region (2021-2026) Table 46. Global Neuraminidase Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 47. Global Neuraminidase Inhibitor Sales by Region (2027-2032) & (K Units) Table 48. Global Neuraminidase Inhibitor Sales Market Share in Volume by Region (2027-2032) Table 49. Global Neuraminidase Inhibitor Sales by Region (2027-2032) & (US$ Million) Table 50. Global Neuraminidase Inhibitor Sales Market Share in Value by Region (2027-2032) Table 51. Global Neuraminidase Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 52. Global Neuraminidase Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 54. Global Neuraminidase Inhibitor Sales Market Share in Volume by Application (2021-2026) Table 55. Global Neuraminidase Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 56. Global Neuraminidase Inhibitor Sales Market Share in Value by Application (2021-2026) Table 57. Global Neuraminidase Inhibitor Price by Application (2021-2026) & (US$/Unit) Table 58. Global Neuraminidase Inhibitor Sales by Application (2027-2032) & (K Units) Table 59. Global Neuraminidase Inhibitor Sales Market Share in Volume by Application (2027-2032) Table 60. Global Neuraminidase Inhibitor Sales by Application (2027-2032) & (US$ Million) Table 61. Global Neuraminidase Inhibitor Sales Market Share in Value by Application (2027-2032) Table 62. Global Neuraminidase Inhibitor Price by Application (2027-2032) & (US$/Unit) Table 63. North America Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 64. North America Neuraminidase Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 66. Europe Neuraminidase Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 68. Asia-Pacific Neuraminidase Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 70. Latin America Neuraminidase Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Neuraminidase Inhibitor Sales by Application (2021-2026) & (K Units) Table 72. Middle East and Africa Neuraminidase Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 73. GlaxoSmithKline Company Information Table 74. GlaxoSmithKline Business Overview Table 75. GlaxoSmithKline Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio Table 77. GlaxoSmithKline Recent Development Table 78. Gilead Sciences Company Information Table 79. Gilead Sciences Business Overview Table 80. Gilead Sciences Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Gilead Sciences Neuraminidase Inhibitor Product Portfolio Table 82. Gilead Sciences Recent Development Table 83. F. Hoffman-La Roche Company Information Table 84. F. Hoffman-La Roche Business Overview Table 85. F. Hoffman-La Roche Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio Table 87. F. Hoffman-La Roche Recent Development Table 88. Daiichi Sankyo Company Information Table 89. Daiichi Sankyo Business Overview Table 90. Daiichi Sankyo Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio Table 92. Daiichi Sankyo Recent Development Table 93. BioCryst Company Information Table 94. BioCryst Business Overview Table 95. BioCryst Neuraminidase Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. BioCryst Neuraminidase Inhibitor Product Portfolio Table 97. BioCryst Recent Development Table 98. North America Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 99. North America Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 100. North America Neuraminidase Inhibitor Sales Market Share by Country (2021-2026) Table 101. North America Neuraminidase Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 102. North America Neuraminidase Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 103. North America Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. North America Neuraminidase Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 105. North America Neuraminidase Inhibitor Market Share by Country (2021-2026) Table 106. North America Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. North America Neuraminidase Inhibitor Market Share Forecast by Country (2027-2032) Table 108. Europe Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 109. Europe Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 110. Europe Neuraminidase Inhibitor Sales Market Share by Country (2021-2026) Table 111. Europe Neuraminidase Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 112. Europe Neuraminidase Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 113. Europe Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Neuraminidase Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Neuraminidase Inhibitor Market Share by Country (2021-2026) Table 116. Europe Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Neuraminidase Inhibitor Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 120. Asia-Pacific Neuraminidase Inhibitor Sales Market Share by Country (2021-2026) Table 121. Asia-Pacific Neuraminidase Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 122. Asia-Pacific Neuraminidase Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 123. Asia-Pacific Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Asia-Pacific Neuraminidase Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 125. Asia-Pacific Neuraminidase Inhibitor Market Share by Country (2021-2026) Table 126. Asia-Pacific Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Asia-Pacific Neuraminidase Inhibitor Market Share Forecast by Country (2027-2032) Table 128. Latin America Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 129. Latin America Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 130. Latin America Neuraminidase Inhibitor Sales Market Share by Country (2021-2026) Table 131. Latin America Neuraminidase Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 132. Latin America Neuraminidase Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 133. Latin America Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Latin America Neuraminidase Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 135. Latin America Neuraminidase Inhibitor Market Share by Country (2021-2026) Table 136. Latin America Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Latin America Neuraminidase Inhibitor Market Share Forecast by Country (2027-2032) Table 138. Middle East and Africa Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 139. Middle East and Africa Neuraminidase Inhibitor Sales by Country (2021-2026) & (K Units) Table 140. Middle East and Africa Neuraminidase Inhibitor Sales Market Share by Country (2021-2026) Table 141. Middle East and Africa Neuraminidase Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 142. Middle East and Africa Neuraminidase Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 143. Middle East and Africa Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Middle East and Africa Neuraminidase Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 145. Middle East and Africa Neuraminidase Inhibitor Market Share by Country (2021-2026) Table 146. Middle East and Africa Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Middle East and Africa Neuraminidase Inhibitor Market Share Forecast by Country (2027-2032) Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Neuraminidase Inhibitor Distributors List Table 151. Neuraminidase Inhibitor Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Neuraminidase Inhibitor Image Figure 2. Global Neuraminidase Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuraminidase Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuraminidase Inhibitor Sales (2021-2032) & (K Units) Figure 5. Oseltamivir Image Figure 6. Global Oseltamivir Sales YoY Growth (2021-2032) & (K Units) Figure 7. Laninamivir Image Figure 8. Global Laninamivir Sales YoY Growth (2021-2032) & (K Units) Figure 9. Peramivir Image Figure 10. Global Peramivir Sales YoY Growth (2021-2032) & (K Units) Figure 11. Zanamivir Image Figure 12. Global Zanamivir Sales YoY Growth (2021-2032) & (K Units) Figure 13. Global Neuraminidase Inhibitor Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Neuraminidase Inhibitor Market Share by Type 2025 VS 2032 Figure 15. North America Neuraminidase Inhibitor Sales Market Share in Volume by Type in 2025 Figure 16. North America Neuraminidase Inhibitor Sales Market Share in Value by Type in 2025 Figure 17. Europe Neuraminidase Inhibitor Sales Market Share in Volume by Type in 2025 Figure 18. Europe Neuraminidase Inhibitor Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Neuraminidase Inhibitor Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Neuraminidase Inhibitor Sales Market Share in Value by Type in 2025 Figure 21. Latin America Neuraminidase Inhibitor Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Neuraminidase Inhibitor Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Neuraminidase Inhibitor Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Neuraminidase Inhibitor Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Neuraminidase Inhibitor Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Hospital Pharmacies Image Figure 28. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 29. Drug Stores Image Figure 30. Global Drug Stores Sales YoY Growth (2021-2032) & (K Units) Figure 31. Retail Stores Image Figure 32. Global Retail Stores Sales YoY Growth (2021-2032) & (K Units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Neuraminidase Inhibitor Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Neuraminidase Inhibitor Market Share by Application 2025 VS 2032 Figure 37. North America Neuraminidase Inhibitor Sales Market Share in Volume by Application in 2025 Figure 38. North America Neuraminidase Inhibitor Sales Market Share in Value by Application in 2025 Figure 39. Europe Neuraminidase Inhibitor Sales Market Share in Volume by Application in 2025 Figure 40. Europe Neuraminidase Inhibitor Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Neuraminidase Inhibitor Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Neuraminidase Inhibitor Sales Market Share in Value by Application in 2025 Figure 43. Latin America Neuraminidase Inhibitor Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Neuraminidase Inhibitor Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Neuraminidase Inhibitor Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Neuraminidase Inhibitor Sales Market Share in Value by Application in 2025 Figure 47. North America Neuraminidase Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Neuraminidase Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Neuraminidase Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Neuraminidase Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Neuraminidase Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Neuraminidase Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Neuraminidase Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Neuraminidase Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Neuraminidase Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Neuraminidase Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Neuraminidase Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Neuraminidase Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Neuraminidase Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Neuraminidase Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Neuraminidase Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Neuraminidase Inhibitor Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Neuraminidase Inhibitor Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir
  • Laninamivir
  • Peramivir
  • Zanamivir
Applications
  • Hospital Pharmacies
  • Drug Stores
  • Retail Stores
  • Others
Companies covered
  • GlaxoSmithKline
  • Gilead Sciences
  • F. Hoffman-La Roche
  • Daiichi Sankyo
  • BioCryst

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuraminidase Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neuraminidase Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neuraminidase Inhibitor Market by Type
  6. 1.3.1 Oseltamivir
  7. 1.3.2 Laninamivir
  8. 1.3.3 Peramivir
  9. 1.3.4 Zanamivir
  10. 1.4 Global Neuraminidase Inhibitor Market Size by Type
  11. 1.4.1 Global Neuraminidase Inhibitor Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Neuraminidase Inhibitor Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Neuraminidase Inhibitor Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Neuraminidase Inhibitor Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Neuraminidase Inhibitor Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Neuraminidase Inhibitor Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Neuraminidase Inhibitor Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Neuraminidase Inhibitor Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neuraminidase Inhibitor Industry Trends
  2. 2.2 Neuraminidase Inhibitor Industry Drivers
  3. 2.3 Neuraminidase Inhibitor Industry Opportunities and Challenges
  4. 2.4 Neuraminidase Inhibitor Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neuraminidase Inhibitor Revenue (2021-2026)
  2. 3.2 Global Top Players by Neuraminidase Inhibitor Sales (2021-2026)
  3. 3.3 Global Top Players by Neuraminidase Inhibitor Price (2021-2026)
  4. 3.4 Global Neuraminidase Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuraminidase Inhibitor Major Company Production Sites & Headquarters
  6. 3.6 Global Neuraminidase Inhibitor Company, Product Type & Application
  7. 3.7 Global Neuraminidase Inhibitor Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuraminidase Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuraminidase Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuraminidase Inhibitor Tier 1, Tier 2, and Tier 3
4 Neuraminidase Inhibitor Regional Status and Outlook
  1. 4.1 Global Neuraminidase Inhibitor Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neuraminidase Inhibitor Historic Market Size by Region
  3. 4.2.1 Global Neuraminidase Inhibitor Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neuraminidase Inhibitor Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neuraminidase Inhibitor Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neuraminidase Inhibitor Forecasted Market Size by Region
  7. 4.3.1 Global Neuraminidase Inhibitor Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neuraminidase Inhibitor Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neuraminidase Inhibitor Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neuraminidase Inhibitor by Application
  1. 5.1 Neuraminidase Inhibitor Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Drug Stores
  4. 5.1.3 Retail Stores
  5. 5.1.4 Others
  6. 5.2 Global Neuraminidase Inhibitor Market Size by Application
  7. 5.2.1 Global Neuraminidase Inhibitor Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Neuraminidase Inhibitor Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Neuraminidase Inhibitor Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Neuraminidase Inhibitor Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Neuraminidase Inhibitor Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Neuraminidase Inhibitor Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Neuraminidase Inhibitor Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Neuraminidase Inhibitor Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 GlaxoSmithKline
  2. 6.1.1 GlaxoSmithKline Company Information
  3. 6.1.2 GlaxoSmithKline Business Overview
  4. 6.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio
  6. 6.1.5 GlaxoSmithKline Recent Developments
  7. 6.2 Gilead Sciences
  8. 6.2.1 Gilead Sciences Company Information
  9. 6.2.2 Gilead Sciences Business Overview
  10. 6.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Gilead Sciences Neuraminidase Inhibitor Product Portfolio
  12. 6.2.5 Gilead Sciences Recent Developments
  13. 6.3 F. Hoffman-La Roche
  14. 6.3.1 F. Hoffman-La Roche Company Information
  15. 6.3.2 F. Hoffman-La Roche Business Overview
  16. 6.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio
  18. 6.3.5 F. Hoffman-La Roche Recent Developments
  19. 6.4 Daiichi Sankyo
  20. 6.4.1 Daiichi Sankyo Company Information
  21. 6.4.2 Daiichi Sankyo Business Overview
  22. 6.4.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio
  24. 6.4.5 Daiichi Sankyo Recent Developments
  25. 6.5 BioCryst
  26. 6.5.1 BioCryst Company Information
  27. 6.5.2 BioCryst Business Overview
  28. 6.5.3 BioCryst Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 BioCryst Neuraminidase Inhibitor Product Portfolio
  30. 6.5.5 BioCryst Recent Developments
7 North America by Country
  1. 7.1 North America Neuraminidase Inhibitor Sales by Country
  2. 7.1.1 North America Neuraminidase Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neuraminidase Inhibitor Sales by Country (2021-2026)
  4. 7.1.3 North America Neuraminidase Inhibitor Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neuraminidase Inhibitor Market Size by Country
  6. 7.2.1 North America Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neuraminidase Inhibitor Market Size by Country (2021-2026)
  8. 7.2.3 North America Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neuraminidase Inhibitor Sales by Country
  2. 8.1.1 Europe Neuraminidase Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neuraminidase Inhibitor Sales by Country (2021-2026)
  4. 8.1.3 Europe Neuraminidase Inhibitor Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neuraminidase Inhibitor Market Size by Country
  6. 8.2.1 Europe Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neuraminidase Inhibitor Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neuraminidase Inhibitor Sales by Country
  2. 9.1.1 Asia-Pacific Neuraminidase Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neuraminidase Inhibitor Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neuraminidase Inhibitor Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neuraminidase Inhibitor Market Size by Country
  6. 9.2.1 Asia-Pacific Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neuraminidase Inhibitor Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neuraminidase Inhibitor Sales by Country
  2. 10.1.1 South America Neuraminidase Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neuraminidase Inhibitor Sales by Country (2021-2026)
  4. 10.1.3 South America Neuraminidase Inhibitor Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neuraminidase Inhibitor Market Size by Country
  6. 10.2.1 South America Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neuraminidase Inhibitor Market Size by Country (2021-2026)
  8. 10.2.3 South America Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neuraminidase Inhibitor Sales by Country
  2. 11.1.1 Middle East and Africa Neuraminidase Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neuraminidase Inhibitor Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neuraminidase Inhibitor Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neuraminidase Inhibitor Market Size by Country
  6. 11.2.1 Middle East and Africa Neuraminidase Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neuraminidase Inhibitor Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neuraminidase Inhibitor Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neuraminidase Inhibitor Value Chain Analysis
  2. 12.1.1 Neuraminidase Inhibitor Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neuraminidase Inhibitor Production Mode & Process
  7. 12.2 Neuraminidase Inhibitor Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neuraminidase Inhibitor Distributors
  10. 12.2.3 Neuraminidase Inhibitor Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst